New cannabis terpene Hashishene discovered

The discovery of a new cannabis terpene, Hashishene, adds to the growing body of research into the chemical composition of cannabis and its derivatives. While this terpene has been identified in high concentrations in hashish, particularly from Moroccan samples, its presence in dried cannabis buds remains limited. This article provides an overview of the current evidence, what patients and carers should know, and guidance on when to seek professional advice.

Key takeaways

• Hashishene is a newly identified terpene found in high concentrations in hashish, particularly from Moroccan samples.
• The terpene is not commonly found in dried cannabis buds, possibly due to differences in drying processes and exposure to light and oxygen.
• The discovery of Hashishene highlights the complexity of cannabis chemistry and the potential for regional variations in terpene profiles.
• While the presence of Hashishene may influence the aroma and taste of hashish, its therapeutic or medicinal effects are not yet well understood.

Evidence base

The identification of Hashishene was reported in a 2014 study published in the *Journal of Chromatography*. The research, titled *Multidimensional analysis of cannabis volatile constituents: identification of 5,5-dimethyl-1-vinylbicyclo[2.1.1]hexane as a volatile marker of hashish, the resin of Cannabis sativa L*, described the discovery of a new compound in hashish samples. The study noted that Hashishene was present in significant amounts—around 14% of the volatile constituents in hash samples, or 0.33% of the total mass. In contrast, it was found in much smaller quantities in dried cannabis buds.

The researchers suggested that the presence of Hashishene in hashish may be linked to the drying process. Specifically, they proposed that beta-myrcene, a common cannabis terpene, could degrade into Hashishene when exposed to light and oxygen, such as during sun-drying. This process may be more prevalent in regions where hashish is traditionally produced, such as parts of Africa, compared to other areas where cannabis is cultivated and dried under different conditions.

While the study provides a clear identification of Hashishene, it does not explore the potential therapeutic or pharmacological effects of the terpene. The research focuses primarily on the chemical composition and analytical methods used to detect the compound. As such, the evidence base for the health benefits or risks associated with Hashishene remains limited.

What patients should know

The discovery of Hashishene is a scientific milestone that contributes to our understanding of cannabis chemistry. However, it is important to note that the presence of this terpene in hashish does not necessarily imply any specific therapeutic benefit. The study highlights the complexity of cannabis and its derivatives, showing that different forms of cannabis—such as hashish and dried buds—can have distinct chemical profiles.

For patients and carers, it is crucial to understand that terpenes like Hashishene may influence the sensory experience of cannabis products, such as taste and aroma. However, the evidence linking these compounds to specific health outcomes is still emerging. While some terpenes are known to have potential therapeutic properties, such as anti-inflammatory or calming effects, the role of Hashishene in these contexts is not yet established.

It is also important to be aware of the legal and regulatory landscape surrounding cannabis products. In the UK, the possession and use of cannabis, including hashish, is illegal under the Misuse of Drugs Act 1971. Patients should be cautious about the legal implications of using cannabis products and should consult with a healthcare professional to understand the potential risks and benefits.

When to speak to a clinician

Patients and carers should consider speaking to a clinician if they are using cannabis products for medicinal purposes or if they have concerns about the safety or legality of such use. It is particularly important to seek professional advice if there are any changes in health status, such as new symptoms or side effects, or if there are questions about the appropriate use of cannabis products.

Red flags or review points to discuss with a clinician include:

• Any changes in physical or mental health
• Concerns about the legal status of cannabis use
• Questions about the potential benefits or risks of specific cannabis products
• The presence of any adverse effects or interactions with other medications

Questions to ask a clinician

• What are the potential health effects of Hashishene or other terpenes found in cannabis products?
• How might the chemical composition of hashish differ from that of dried cannabis buds?
• Are there any known therapeutic benefits of terpenes like Hashishene?

Source trail

• [Multidimensional analysis of cannabis volatile constituents: identification of 5,5-dimethyl-1-vinylbicyclo[2.1.1]hexane as a volatile marker of hashish, the resin of Cannabis sativa L](https://www.academia.edu/19290659/Multidimensionalanalysisofcannabisvolatileconstituentsidentificationof55-dimethyl-1-vinylbicyclo2.1.1hexaneasavolatilemarkerofhashishtheresinofCannabissativa_L)
• NHS guidance on cannabis and its legal status
• Official guidance on the use of cannabis products for medicinal purposes